BSE Live
Mar 27, 16:01Prev. Close
1307.70
Open Price
1330.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 27, 15:57Prev. Close
1307.80
Open Price
1307.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1314.20 (115)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,358.45 | 2,402.92 | 1,614.35 | 1,637.48 | 4,193.01 | |
| Net CashFlow From Operating Activities | 1,645.79 | 1,714.80 | 1,821.16 | 3,726.71 | 2,994.41 | |
| Net Cash Used In Investing Activities | -2,065.90 | -159.96 | -3,459.68 | -1,613.51 | -2,648.73 | |
| Net Cash Used From Financing Activities | 616.31 | -1,837.03 | 1,719.48 | -2,447.54 | -27.94 | |
| Foreign Exchange Gains / Losses | 15.74 | 8.38 | 0.48 | -1.03 | -1.51 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 211.94 | -273.81 | 81.44 | -335.37 | 316.23 | |
| Cash And Cash Equivalents Begin of Year | 83.32 | 357.13 | 48.21 | 383.58 | 67.35 | |
| Cash And Cash Equivalents End Of Year | 295.26 | 83.32 | 129.65 | 48.21 | 383.58 |
27.03.2026
24.03.2026
24.03.2026
23.03.2026
10.02.2026
Aurobindo Pharm Standalone December 2025 Net Sales at Rs 2,747.28 crore, down 5.81% Y-o-Y
10.02.2026
Aurobindo Pharm Consolidated December 2025 Net Sales at Rs 8,645.90 crore, up 8.36% Y-o-Y
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
27.03.2026
26.03.2026
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth